Although AZD0156 alone was not effective in inhibiting the growth of cancer cells in a xenograft model of colon cancer (SW620) or patient-derived xenograft model of BRCA2-mutant breast cancer, the combination of AZD0156 with irinotecan (colon cancer) or olaparib (breast cancer) was shown to result in synergistic inhibitory effects [69]. Here, BRCA2 is linked to colonic neoplasm.